PAREXEL International Corp (NASDAQ:PRXL)

CAPS Rating: 5 out of 5

The Company provides a range of expertise in clinical research, medical communications services, consulting, and informatics and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries.

Results 1 - 20 of 32 : 1 2 Next »

Recs

0
Member Avatar umight (48.54) Submitted: 11/7/2014 9:39:03 AM : Outperform Start Price: $53.17 PRXL Score: +5.89

A well run, steady performer in the hot Health Care sector.

Recs

0
Member Avatar clifton (< 20) Submitted: 5/22/2014 8:44:24 AM : Outperform Start Price: $48.21 PRXL Score: +9.60

Small pharma is growing and cannot afford to have clinical research teams in house. Big pharma will increasingly outsource discovery and early development functions. parexel has a long standing good reputation in its field which is important in drug development.

Recs

0
Member Avatar TMF42 (94.91) Submitted: 1/15/2014 9:42:11 AM : Outperform Start Price: $46.84 PRXL Score: +10.15

Parexel is one of the world's largest and most respected contract research organizations (CROs). Over more than 30 years, it has built a stellar reputation on helping drug makers navigate complex clinical trial processes quickly, which has enabled it to cement important relationships and have a role in developing more than 90% of the top 200 selling drugs.

From 2004 to 2013, the number of development dollars outsourced to CROs (outsourcing penetration) has increased by almost 50%. Outsourcing is a cheaper alternative to the traditional high-fixed-cost model of staffing lots of white coats across various therapeutic specialties all around the globe. As regulators require more efficacy data, larger patient participation, and increasingly global results, navigating the challenges of the 110,000-plus trials being conducted globally has become frustratingly complex, making large, proven CROs with expertise and global capabilities more of a value-adding partner than a transactional customer.

Parexel has shown leadership in ushering in the partnership model and will soon have hard data on early partnerships to bring to the bargaining table to win new customers. Additionally, Parexel's technology segment, Perceptive Informatics, is a leader in several e-clinical applications that turn archaic trial-related processes digital, and should become increasingly profitable as it grows. Its underlying market is expected to increase by at least 10% per year , and if the segment's MyTrials solution becomes the industry standard platform for accessing e-clinical apps, growth should handily eclipse that.

Recs

0
Member Avatar cavemantrader (79.78) Submitted: 12/5/2013 2:22:47 PM : Outperform Start Price: $39.65 PRXL Score: +29.13

Bear raid complete, funds loading up for the next 52 week high! Super good value here, a best in breed poised for some huge upside. Growing margins, and revenue. Contracts continuing to line up! A nice core holding for any portfolio.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:48:21 PM : Outperform Start Price: $48.16 PRXL Score: -5.12

Long. Pricey at 32x ttm, 21x fye earnings, but revenue growth of 18% and earnings growth of 69% justify it.

Recs

0
Member Avatar otherAquanaut (99.79) Submitted: 8/13/2013 12:46:46 PM : Outperform Start Price: $50.99 PRXL Score: -9.99

Note to self: Climbing for a long time. Review often.

Recs

1
Member Avatar GMoney321 (< 20) Submitted: 5/25/2013 11:49:31 AM : Outperform Start Price: $46.16 PRXL Score: +0.40

Double digit growth

Recs

1
Member Avatar CellBlock9 (92.62) Submitted: 5/6/2013 1:25:13 PM : Outperform Start Price: $44.04 PRXL Score: +2.41

s&p 5 star

Recs

0
Member Avatar eat251heart (< 20) Submitted: 4/4/2013 11:31:06 AM : Outperform Start Price: $39.67 PRXL Score: +11.67

Healthcare is a growing market and concern.Specializing in clinical research and communications are a winner in my book.

Recs

0
Member Avatar FlyingTiger51 (< 20) Submitted: 6/1/2012 6:53:56 PM : Underperform Start Price: $25.55 PRXL Score: -63.29

Net profit margin comparing to PRXL's competitiors i.e. Quintile, Covance, and PPDI historically has been at least 10 points below. PRXL's cut throat management style to improve short term profitability can only cause more valuable employees and contirbutors deaprting the company.

Recs

1
Member Avatar KimLanners (< 20) Submitted: 5/3/2011 4:16:30 PM : Outperform Start Price: $23.00 PRXL Score: +96.79

medical with upside

Recs

0
Member Avatar Gemini846 (46.67) Submitted: 8/30/2010 8:14:22 AM : Outperform Start Price: $21.12 PRXL Score: +77.42

It's never too early to go Christmas shopping. Picking a broad basket of stocks that seem favorable when expecting a short term bull rally.

Recs

1
Member Avatar CroMagnon1948 (< 20) Submitted: 1/15/2010 11:46:09 AM : Outperform Start Price: $17.54 PRXL Score: +144.78

Another sell-off buying opportunity.

Recs

1
Member Avatar hondo928 (99.50) Submitted: 3/10/2009 4:18:16 PM : Outperform Start Price: $8.81 PRXL Score: +409.30

Because I can bet the sector will win, without the risk of crappy management....Pfizer *cough cough*

Recs

1
Member Avatar PennyStockFool (31.77) Submitted: 1/27/2009 4:05:42 PM : Underperform Start Price: $9.67 PRXL Score: -349.11

Taking today's (1/27) 30% gain on this stock and going Thumbs Down for a few weeks.

Recs

1
Member Avatar GKuhfeldt (54.61) Submitted: 1/27/2009 3:58:59 PM : Outperform Start Price: $9.58 PRXL Score: +349.29

So cheap.

Recs

1
Member Avatar BobLangley (81.08) Submitted: 10/20/2008 11:22:03 PM : Outperform Start Price: $21.52 PRXL Score: +47.65

Considerable backlog exists for the services of this clinical research and marketing company whose stock has taken an unjustified hit of late.

Recs

0
Member Avatar JP1031 (63.88) Submitted: 10/10/2008 5:02:52 PM : Outperform Start Price: $22.90 PRXL Score: +25.77

This stock has consistently outperformed the S&P 500 and seems to be undervalued due to the recent sell off. No debt makes them very attractive in this market.

Recs

0
Member Avatar suhsido1 (< 20) Submitted: 9/9/2008 4:58:29 AM : Outperform Start Price: $31.14 PRXL Score: +16.21

Clinical research. 4 star.

Recs

0
Member Avatar ivoirien (42.09) Submitted: 7/16/2008 9:35:59 PM : Outperform Start Price: $27.24 PRXL Score: +40.01

Breakout today from cup-with-handle, right at confluence of 50-day and 200-day MAs

Results 1 - 20 of 32 : 1 2 Next »

Featured Broker Partners


Advertisement